21 results on '"Del Toro G"'
Search Results
2. Moyamoya Syndrome Treated With Encephaloduroarteriosynangiosis Followed by Bone Marrow Transplantation in a Patient With Sickle Cell Disease: A Case Report
3. A Study Of The Barriers Preventing Access Of U.S. Pediatric Sickle Cell Disease Patients To Technologies That Facilitate Compatible Sibling Hematopoietic Cell Transplantation
4. Intra-Arterial Steroids For Systemic Steroid Resistant Graft-Vs-Host Disease
5. 212: Adenovirus (ADV) infections following allogeneic stem cell transplant (alloSCT) in children and adolescent recepients
6. 185: Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma
7. 3: Reduced Intensity (RI) aLlogeneic Cord Blood Hematopoietic Cell Transplantation (Allo-CBHCT) in Pediatric Patients with Malignant and Non-Malignant Diseases
8. Reduced intensity (RI) allogeneic cord blood hematopoietic cell transplantation (Allo CBHCT) in pediatric patients with malignant and non-malignant diseases
9. Tacrolimus (FK-506) and mycophenolate mofetil (MMF) GVHD prophylaxis in pediatric allogeneic SCT (AlloSCT) recipients: altered MMF pharmacokinetics (pk) associated with acute (A)GVHD
10. A pilot study of myeloablative (MA) autologous stem cell transplantation (AUTOSCT) followed by reduced intensity (RI) allogeneic transplantation (ALLOSCT) in children and young adults with relapsed/refractory lymphoma
11. Reduced intensity conditioning and allogeneic stem cell transplantation (RIAlloSCT) from unrelated cord blood and matched family donors in children and adolescent recipients results in sustained donor chimerism
12. 120Unrelated cord blood transplantation (UCBT) from HLA disparate donors results in a very low risk of ≥grade II acute & chronic GVHD: CD34 dose and non-TBI conditioning predict for significantly improved survival
13. Alternate day ganciclovir and foscarnet is safe and effective in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients
14. A pilot study of myeloablative (MA) autologous stem cell (autoSCT) followed by reduced intensity (RI) allogeneic transplantation (AlloSCT) in children and adolescents with relapsed hodgkin’s disease (HD) and non-hodgkin’s lymphoma (NHL)
15. Higher clearance rates of mycophenolate mofetil (MMF) in pediatric allogeneic stem cell transplant (allosct) recipients
16. Sequential administration of sargramostim (GM-CSF) and filgrastim (G-CSF) in pediatric allogeneic stem cell transplant (allosct) recipients undergoing myeloablative (MA) conditioning: Cost-effective and more rapid platelet recovery in UCB recipients
17. 253Alternate day ganciclovir/foscarnet (Gan/Fos) for cytomegalovirus prophylaxis in at risk allogeneic stem cell transplant related and unrelated recipients is 100% effective in preventing CMV infections
18. 205Non-myeloablative allogenic stem cell transplant (NASCT) with unrelated cord blood and matched family donors in children and adolescents
19. 197A pilot study of myeloablative (MA) autologous stem cell transplantation (Auto SCT) followed by reduced intensity (RI) allogeneic transplantation (ALLO SCT) in children and young adults with relapsed lymphoma
20. 94 Tacrolimus (FK-506) and mycophenolate mofetil (MMF) GVHD prophylaxis in allogeneic SCT (alloSCT) recipients: Altered MMF pharmacokinetics (PK) associated with AGVHD
21. 185: Feasibility of autologous stem cell transplant followed by reduced intensity allogeneic stem cell transplantation for high risk neuroblastoma A single institution pilot study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.